SEARCH

SEARCH BY CITATION

REFERENCES

  • Armitage P, Berry G, Matthews J (2002): Statistical methods in medical research, 4th ed.Blackwell Science Ltd.
  • Barker PB, Bonekamp D, Riedy G, Smith M (2006): Quantitation of NAA in the brain by magnetic resonance spectroscopy. Adv Exp Med Biol 576:183197.
  • Bitsch A, Bruhn H, Vougioukas V, Stringaris A, Lassmann H, Frahm J, Bruck W (1999): Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR Am J Neuroradiol 20:16191627.
  • Bodini B, Khaleeli Z, Cercignani M, Miller DH, Thompson AJ, Ciccarelli O (2009): Exploring the relationship between white matter and gray matter damage in early primary progressive multiple sclerosis: An in vivo study with TBSS and VBM. Hum Brain Mapp 30:28522861.
  • Bramow S, Frischer JM, Lassmann H, Koch-Henriksen N, Lucchinetti CF, Sorensen PS, Laursen H (2010): Demyelination versus remyelination in progressive multiple sclerosis. Brain 133:29832998.
  • Caramanos Z, Narayanan S, Arnold DL (2005): 1H-MRS quantification of tNA and tCr in patients with multiple sclerosis: a meta-analytic review. Brain 128:24832506.
  • Chard DT, Griffin CM, McLean MA, Kapeller P, Kapoor R, Thompson AJ, Miller DH (2002): Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain 125:23422352.
  • Ciccarelli O, Toosy AT, De Stefano N, Wheeler-Kingshott CA, Miller DH, Thompson AJ (2010a): Assessing neuronal metabolism in vivo by modelling imaging measures. J Neurosci 30:15030.
  • Ciccarelli O, Altmann DR, McLean MA, Wheeler-Kingshott CA, Wimpey K, Miller DH, Thompson AJ (2010b): Spinal cord repair in MS: Does mitochondrial metabolism play a role?Neurology 74:721727.
  • Ciccarelli O, Wheeler-Kingshott CA, McLean MA, Cercignani M, Wimpey K, Miller DH, Thompson AJ (2007): Spinal cord spectroscopy and diffusion-based tractography to assess acute disability in multiple sclerosis. Brain 130:22202231.
  • Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, Syndulko K, Weinshenker BG, Antel JP, Confavreux C, Ellison GW, Lublin F, Miller AE, Rao SM, Reingold S, Thompson A, Willoughby E (1999): Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 122 ( Pt 5):871882.
  • Di FM, Chiasserini D, Tozzi A, Picconi B, Calabresi P (2010): Mitochondria and the link between neuroinflammation and neurodegeneration. J Alzheimers Dis 20 ( Suppl 2):S369S379.
  • Fernando KT, McLean MA, Chard DT, MacManus DG, Dalton CM, Miszkiel KA, Gordon RM, Plant GT, Thompson AJ, Miller DH (2004): Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis. Brain 127:13611369.
  • Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Lassmann H (2009): The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132:11751189.
  • Geurts JJ, Barkhof F, Castelijns JA, Uitdehaag BM, Polman CH, Pouwels PJ (2004): Quantitative 1H-MRS of healthy human cortex, hippocampus, and thalamus: metabolite concentrations, quantification precision, and reproducibility. J Magn Reson Imaging 20:366371.
  • Geurts JJ, Reuling IE, Vrenken H, Uitdehaag BM, Polman CH, Castelijns JA, Barkhof F, Pouwels PJ (2006): MR spectroscopic evidence for thalamic and hippocampal, but not cortical, damage in multiple sclerosis. Magn Reson Med 55:478483.
  • Giorgio A, Palace J, Johansen-Berg H, Smith SM, Ropele S, Fuchs S, Wallner-Blazek M, Enzinger C, Fazekas F (2010): Relationships of brain white matter microstructure with clinical and MR measures in relapsing-remitting multiple sclerosis. J Magn Reson Imaging 31:309316.
  • Goldsmith J, Crainiceanu CM, Caffo BS, Reich DS (2011): Penalized functional regression analysis of white-matter tract profiles in multiple sclerosis. Neuroimage 57:431439.
  • Gorgoraptis N, Wheeler-Kingshott CA, Jenkins TM, Altmann DR, Miller DH, Thompson AJ, Ciccarelli O (2010): Combining tractography and cortical measures to test system-specific hypotheses in multiple sclerosis. Mult Scler 16:555565.
  • Hajek M, Dezortova M (2008): Introduction to clinical in vivo MR spectroscopy. Eur J Radiol 67:185193.
  • Hoogervorst EL, Kalkers NF, Uitdehaag BM, Polman CH (2002): A study validating changes in the multiple sclerosis functional composite. Arch Neurol 59:113116.
  • Jansen JF, Backes WH, Nicolay K, Kooi ME (2006): 1H MR spectroscopy of the brain: Absolute quantification of metabolites. Radiology 240:318332.
  • Khaleeli Z, Altmann DR, Cercignani M, Ciccarelli O, Miller DH, Thompson AJ (2008): Magnetization transfer ratio in gray matter: a potential surrogate marker for progression in early primary progressive multiple sclerosis. Arch Neurol 65:14541459.
  • Khaleeli Z, Sastre-Garriga J, Ciccarelli O, Miller DH, Thompson AJ (2007): Magnetisation transfer ratio in the normal appearing white matter predicts progression of disability over 1 year in early primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 78:10761082.
  • Kirov II, Patil V, Babb JS, Rusinek H, Herbert J, Gonen O (2009): MR spectroscopy indicates diffuse multiple sclerosis activity during remission. J Neurol Neurosurg Psychiatry 80:13301336.
  • Kurtzke JF (1983): Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 33:14441452.
  • Lee MA, Blamire AM, Pendlebury S, Ho KH, Mills KR, Styles P, Palace J, Matthews PM (2000): Axonal injury or loss in the internal capsule and motor impairment in multiple sclerosis. Arch Neurol 57:6570.
  • Lublin FD, Reingold SC (1996): Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on clinical trials of new agents in multiple sclerosis. Neurology 46:907911.
  • Marliani AF, Clementi V, Albini RL, Agati R, Carpenzano M, Salvi F, Leonardi M (2010): Quantitative cervical spinal cord 3T proton MR spectroscopy in multiple sclerosis. AJNR Am J Neuroradiol 31:180184.
  • Marliani AF, Clementi V, bini-Riccioli L, Agati R, Leonardi M (2007): Quantitative proton magnetic resonance spectroscopy of the human cervical spinal cord at 3 Tesla. Magn Reson Med 57:160163.
  • Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AM (2007): N-acetylaspartate in the CNS: From neurodiagnostics to neurobiology. Prog Neurobiol 81:89131.
  • Moll NM, Rietsch AM, Thomas S, Ransohoff AJ, Lee JC, Fox R, Chang A, Ransohoff RM, Fisher E (2011): Multiple sclerosis normal-appearing white matter: Pathology-imaging correlations. Ann Neurol 70:764773.
  • Pagani E, Filippi M, Rocca MA, Horsfield MA (2005): A method for obtaining tract-specific diffusion tensor MRI measurements in the presence of disease: Application to patients with clinically isolated syndromes suggestive of multiple sclerosis. Neuroimage 26:258265.
  • Pan JW, Hetherington HP, Vaughan JT, Mitchell G, Pohost GM, Whitaker JN (1996): Evaluation of multiple sclerosis by 1H spectroscopic imaging at 4.1 T. Magn Reson Med 36:7277.
  • Plummer DL. (1992): Dispimage: A display and analysis tool for medical images. Rev Neuroradiol 5:489495.
  • Provencher SW (1993): Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 30:672679.
  • Ransohoff RM, Perry VH (2009): Microglial physiology: Unique stimuli, specialized responses. Annu Rev Immunol 27:119145.
  • Reich DS, Smith SA, Zackowski KM, Gordon-Lipkin EM, Jones CK, Farrell JA, Mori S, van Zijl PC, Calabresi PA (2007): Multiparametric magnetic resonance imaging analysis of the corticospinal tract in multiple sclerosis. Neuroimage 38:271279.
  • Sailer M, O'Riordan JI, Thompson AJ, Kingsley DP, MacManus DG, McDonald WI, Miller DH (1999): Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. Neurology 52:599606.
  • Sastre-Garriga J, Ingle GT, Chard DT, Ramio-Torrenta L, McLean MA, Miller DH, Thompson AJ (2005): Metabolite changes in normal-appearing gray and white matter are linked with disability in early primary progressive multiple sclerosis. Arch Neurol 62:569573.
  • Suhy J, Rooney WD, Goodkin DE, Capizzano AA, Soher BJ, Maudsley AA, Waubant E, Andersson PB, Weiner MW (2000): 1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS. Mult Scler 6:148155.
  • Summers M, Swanton J, Fernando K, Dalton C, Miller DH, Cipolotti L, Ron MA (2008): Cognitive impairment in multiple sclerosis can be predicted by imaging early in the disease. J Neurol Neurosurg Psychiatry 79:955958.
  • Tallantyre EC, Bo L, Al-Rawashdeh O, Owens T, Polman CH, Lowe J, Evangelou N (2009): Greater loss of axons in primary progressive multiple sclerosis plaques compared to secondary progressive disease. Brain 132:11901199.
  • Thompson AJ, Montalban X, Barkhof F, Brochet B, Filippi M, Miller DH, Polman CH, Stevenson VL, McDonald WI (2000): Diagnostic criteria for primary progressive multiple sclerosis: A position paper. Ann Neurol 47:831835.
  • Tiberio M, Chard DT, Altmann DR, Davies G, Griffin CM, McLean MA, Rashid W, Sastre-Garriga J, Thompson AJ, Miller DH (2006): Metabolite changes in early relapsing-remitting multiple sclerosis. A two year follow-up study. J Neurol 253:224230.
  • Tur C, Khaleeli Z, Ciccarelli O, Altmann DR, Cercignani M, Miller DH, Thompson AJ (2011): Complementary roles of grey matter MTR and T2 lesions in predicting progression in early PPMS. J Neurol Neurosurg Psychiatry 82:423428.
  • Vrenken H, Barkhof F, Uitdehaag BM, Castelijns JA, Polman CH, Pouwels PJ (2005): MR spectroscopic evidence for glial increase but not for neuro-axonal damage in MS normal-appearing white matter. Magn Reson Med 53:256266.
  • Wyss M, Kaddurah-Daouk R (2000): Creatine and creatinine metabolism. Physiol Rev 80:11071213.